Content Currently Unavailable
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
Content Currently Unavailable